发明名称 |
COMBINATION THERAPY COMPRISING A DIARYL UREA COMPOUND AND A PI3, AKT KINASE OR MTOR INHIBITORS (RAPAMYCINS) FOR CANCER TREATMENT |
摘要 |
<p>The present invention relates to pharmaceutical compositions and combinations for treating cancer, comprising a diaryl urea compound e.g. 4 {4- [3- (4-chloro-3-trifluoromethylphenyl) -ureido] -3-fluorophenoxy}-pyridine-2- carboxylis acid methylamide and an PI3K/AKT signaling pathway inhibitor. The PI3K/AKI signaling pathway inhibitor comprises PI3 inhibitors {like celecoxilo, viridins, wortmannins} , AKT kinase inhibitors {like perifosine, triciribine} and mTOR inhibitors {like the rapamycins temsirolimus and evorolimus}.</p> |
申请公布号 |
WO2006125540(A1) |
申请公布日期 |
2006.11.30 |
申请号 |
WO2006EP04524 |
申请日期 |
2006.05.13 |
申请人 |
BAYER HEALTHCARE AG;SCHEURING, URBAN;BERNARD, INGO |
发明人 |
SCHEURING, URBAN;BERNARD, INGO |
分类号 |
A61K31/4412;A61K31/436;A61P35/00 |
主分类号 |
A61K31/4412 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|